• Reactive Oxygen Species Assay Kit: Mechanism

  2026-08-31

  Explore how the Reactive Oxygen Species Assay Kit (DHE) converts intracellular superoxide into a mechanistically useful endpoint. This guide connects DHE fluorescence with the PINK1–Parkin mitophagy findings reported in pulmonary fibrosis research and explains how to interpret the assay rigorously.

• FKBP9, ER Stress, and Glioblastoma Malignancy

  2026-08-31

  Xu et al. identify FKBP9 as an ER-resident immunophilin that promotes glioblastoma growth, invasion, and tumor formation while protecting cells from ER stress. The study connects FKBP9 to ASK1–p38MAPK signaling and the IRE1α–XBP1 unfolded protein response, providing a mechanistic framework for studying stress-adapted GBM biology.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-30

  Song and colleagues show that murine norovirus exploits the membrane-rupture protein NINJ1 to release the viral immunomodulatory protein NS1 through an unconventional, caspase-3-dependent pathway. The study combines CRISPR screening, infection models, protein-interaction analysis, mutagenesis, and mouse experiments to connect selective viral secretion with enteric infection.

• IEM-1925 Against Soman-Induced Status Epilepticus

  2026-08-29

  A 2026 NeuroToxicology study examined IEM-1925 as a dual AMPA/NMDA glutamate receptor strategy for soman-induced status epilepticus, reporting coordinated seizure suppression, hippocampal protection, and improved behavioral outcomes in rats. Its main contribution is to connect acute electrographic seizure control with longer-term neurodegeneration and cognition endpoints, while highlighting limitations of transient benzodiazepine-based control.

• Panobinostat (LBH589): An ECM–Immune Assay Lens

  2026-08-28

  Panobinostat (LBH589) offers a powerful way to connect HDAC-dependent epigenetic regulation with macrophage–fibroblast extracellular-matrix remodeling. This article translates recent form-deprivation myopia findings into a rigorous assay framework while distinguishing pharmacological pathway effects from cell-type-specific causality.

• 10058-F4: Practical c-Myc-Max Inhibition Workflows

  2026-08-28

  10058-F4 enables time-controlled disruption of c-Myc/Max signaling in apoptosis assays, acute myeloid leukemia research, and prostate cancer models. This guide connects compound handling with target-engagement readouts, experimental controls, and a cautious extension toward APEX2–TERT studies.

• ECM Internalisation, p38β, and Cancer Cell Migration

  2026-08-27

  Martinez et al. developed a live-cell, high-content assay that revealed extracellular matrix internalisation as an active regulator of invasive carcinoma-cell migration. Their data connect α2β1 integrin, MAP3K1, MAPK11/p38β, PPP2R1A, and NHE1 to ECM uptake and lysosomal processing, creating a mechanistic framework for studying tumour invasion and pathway-directed experiments.

• HOXC8, Caspase-1, and Pyroptosis in Lung Tumors

  2026-08-27

  The reference study identifies HOXC8 as a transcriptional suppressor of CASP1 in non-small cell lung carcinoma, linking HOXC8 loss to ASC-independent pyroptosis rather than conventional apoptotic death. Its genetic, pharmacological, transcriptional, and tumor-model evidence suggests that restoring caspase-1-driven cell death may be a useful strategy for understanding HOXC8-dependent lung tumorigenesis.

• From Gut Microbial Injury to RIP1 Biology

  2026-08-26

  A translational framework for using Necrostatin-1 to test whether microbial virulence, necroptosis, and tissue injury converge on RIP1 kinase signaling in inflammatory disease models.

• CD47 Inhibits Phagocytosis via Vav Dephosphorylation

  2026-08-26

  Miller et al. show that CD47 suppresses macrophage phagocytosis by blocking Vav phosphorylation downstream of Syk, thereby limiting Rac-dependent actin remodeling rather than preventing Vav recruitment or Syk activation. The study distinguishes Rac-based reaching from Rho-based sinking and identifies Vav as a mechanistic control point linking inhibitory CD47–SIRPα signaling to phagocytic behavior.

• Cycloheximide: Reading Protein Turnover in Cancer

  2026-08-25

  A mechanistic and translational guide to using Cycloheximide as a controlled protein biosynthesis inhibitor for dissecting cyclin D1 turnover, apoptosis, and model-specific therapeutic hypotheses.

• mTORC1 Oscillations Shape Cell-Cycle Progression

  2026-08-25

  Joshi et al. show that mTORC1 activity is not constant during proliferation: it is lowest in mitosis and G1 and highest during S and G2. Their results link this oscillation to interphase progression, Chk1/Wee1-dependent mitotic entry, and phase-specific sensitivity to autophagy induction.

• Tetrandrine: A Mechanistic Guide to Assay Design

  2026-08-24

  Tetrandrine is a versatile Tetrandrine alkaloid for calcium signaling, ion channel modulation studies, and disease-model research. This guide connects its physicochemical profile with rigorous assay design and explains what a SARS-CoV-2 NSP15 screening study can—and cannot—justify experimentally.

• AO/PI Double Staining Kit: Practical Workflow

  2026-08-24

  The AO/PI Double Staining Kit provides a rapid fluorescence-based approach for separating viable, apoptotic, and necrotic cell populations in one preparation. It is suitable for screening cell viability, apoptosis detection, and necrosis detection, but it should not be treated as a stand-alone mechanistic assay or a replacement for orthogonal confirmation of cell-death pathways.

• Enzalutamide, Senescence, and Senolytic Sensitivity

  2026-08-23

  The reference study shows that DNA damage and Enzalutamide produce distinct senescence phenotypes in prostate cancer cells, with only DNA damage-associated senescence creating strong sensitivity to Bcl-xL-directed senolysis. These findings support context-dependent profiling of therapy-induced senescence before selecting combination treatments or interpreting apoptosis responses.

7114 records 5/475 page Previous Next 12345 下5页 Last page